Shanghai, China, May 11, 2024 - Shanghai Novamab Biopharmaceuticals Co., Ltd., a biotechnology company dedicated to the research and development of innovative nanobody drugs, announced that Dr. Yakun Wan, the founder and chairman of Novmab, has been successively invited to attend the 2024 American Thoracic Society International Conference (referred to as "ATS") and the 2024 BIO International Convention (referred to as "BIO").

The 2024 American Thoracic Society (ATS) International Conference will be held from May 17 to 22, 2024, in San Diego, USA. The theme of this year's ATS conference is "Breakthrough Research, Excellence in Patient Care." During the conference, Novamab will present the latest clinical progress of its inhaled nanobody drugs at the Respiratory Innovative Summit and Thematic Poster Session. 

01- Novamab——A Clinical-Stage Pioneer Focused on Innovative Inhalable sdAb for Respiratory Diseases 

—Session Type : Respiratory Innovative Summit-Presentation

—Session Date and Time: 5/18/2024  8:46 AM-8:50 AM PST

—Location：Manchester Grand Hyatt 1 Market Place 

02-A Clinical-Stage Pioneer Focused on Innovative Inhalable Drugs for Respiratory Diseases 

—Session Type : Respiratory Innovative Summit-Poster 

—Session Date and Time: 5/18/2024  7:15 AM-12:00 AM PST

—Location：Manchester Grand Hyatt 1 Market Place

03-Clinical Phase II: Safety and Efficacy of Inhaled Single Domain Antibodies in Healthy Volunteers and Moderate-to-Severe Asthma Patients 

—Session Type : A34. Late Breaking Abstracts in Asthma and Allergic Inflammation Poster 

—Session Date and Time: 5/19/2024  11:30 AM-13:15 AM PST 

—Location：Area D (Hall A-B2, Ground Level), P394

The 2024 BIO International Convention will be held from June 3 to 6, 2024, in San Diego, USA. At that time, Dr. Yakun Wan will introduce Novamab's core pipeline and R&D progress through a conference presentation. 

—Session Type : Presentation 

—Session Date and Time: 6/3/2024  4:00 PM-4:15 PM PST 

—Location：Hall A Comany Presentation Theater 2

Novamab is dedicated to the research and development of nanobody drugs, with a strong foundation in the field of respiratory diseases. We continuously expand international cooperation and sincerely invite you to participate and interact at the event. Our chairman, Dr. Yakun Wan, will join peers from around the world to engage in in-depth discussions and exchanges on the research and development of inhaled macromolecular drugs in the field of respiratory diseases.

About the American Thoracic Society (ATS) International Conference 

The American Thoracic Society (ATS) Annual Meeting is the largest and most influential professional academic conference in the field of respiratory medicine worldwide. Each year, it attracts more than 14,000 participants from around the globe to discuss the latest research progress in respiratory medical care, breakthrough studies, and cutting-edge science. Many significant international research findings and discoveries are also first released at the ATS Annual Meeting. Established in 1905, the American Thoracic Society (ATS) is the most authoritative respiratory academic organization in the world and currently has over 16,000 members. ATS is committed to improving global health by promoting research in the fields of pulmonary diseases, critical care, and sleep medicine, as well as patient care and public health.

About BIO International Convention

Established in 1993, BIO is the world's largest biotechnology industry event, bringing together leading biopharmaceutical companies, investors, and partners from around the globe. Numerous cooperation activities are held during the conference, providing a platform for companies, science and technology parks, and research and development institutions from various countries to promote and showcase their work. The event is organized by the Biotechnology Innovation Organization (BIO), which is the largest biotechnology industry association representing biotechnology companies, academic institutions, and related organizations worldwide.

About Novamab 

Shanghai Novamab Biopharmaceuticals Co., Ltd. is an innovative biopharmaceutical enterprise dedicated to the research and industrialization of nanobody drugs. The company was established in October 2017 and is located in the Shanghai International Medical Park. It has established a complete research and development, CMC, and pilot production platform and system, and is currently the only company in China with the capability for full-process development of nanobodies. Novamab has built a 500 L Pichia pastoris nanobody GMP pilot production workshop, filling an industry gap in this field with high scarcity and competitiveness. 

As of April 2024, more than 80 domestic and foreign invention patents have been applied for, and 29 have been authorized. Novamab has developed dozens of nanobody drugs, with a pipeline covering fields such as respiratory system, autoimmune, ophthalmology, and oncology. Currently, it has obtained four clinical approvals. The LQ036 and LQ043H products under development by Novamab have overturned the existing treatment methods for respiratory diseases, both of which are the world's first inhaled nanobody drugs of their respective target.